We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma.
- Authors
Yamashita, Shimpei; Hamamoto, Shuzo; Furukawa, Junya; Fujita, Kazutoshi; Takahashi, Masayuki; Miyake, Makito; Ito, Noriyuki; Iwamoto, Hideto; Kohjimoto, Yasuo; Hara, Isao
- Abstract
FAN score is reportedly associated with prognostic outcomes in patients with urothelial carcinoma being treated with immune check point inhibitors. However, the prognostic impact of pre-treatment FAN score in patients with metastatic renal cell carcinoma (RCC) treated with nivolumab plus ipilimumab remains unclear. We retrospectively evaluated the association between pre-treatment FAN score and prognostic outcomes in 154 patients with metastatic RCC treated with nivolumab plus ipilimumab. The pre-treatment FAN score was '0' in 56 patients (36%), '1' in 60 patients (40%), '2' in 37 patients (24%) and '3' in one patient (1%). Progression-free survival was not significantly different between patients with different FAN scores, but second progression-free survival (PFS2), cancer-specific survival (CSS) and overall survival (OS) were significantly different. In multivariable Cox proportional hazard analyses, FAN score ≥ 2 was a significant predictor of poor PFS2 (vs. FAN score 0, HR: 2.43, 95% CI 1.21–4.87, P = 0.01), poor CSS (vs. FAN score 0, HR: 2.71, 95% CI 1.13–6.47, P = 0.02) and poor OS (vs. FAN score 0, HR: 2.42, 95% CI 1.11–5.25, P = 0.02). High pre-treatment FAN score could be a significant independent predictor of poor prognosis in patients receiving nivolumab plus ipilimumab for metastatic RCC.
- Subjects
PROGRESSION-free survival; RENAL cell carcinoma; IMMUNE checkpoint inhibitors; NIVOLUMAB; IPILIMUMAB; BREAST; OVERALL survival
- Publication
Scientific Reports, 2024, Vol 14, Issue 1, p1
- ISSN
2045-2322
- Publication type
Article
- DOI
10.1038/s41598-024-63403-2